Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500
If you need additional assistance or information regarding the company, please
send an Email to:
webinfo@neurochem.com.
December 5, 2000
- Neurochem announces the achievement of an important drug development milestone for
Alzheimer's disease
Neurochem Inc. (TSX : NRM) announced today the achievement of an important drug development
milestone for the advancement of an anti-amyloid drug candidate, for the treatment of
Alzheimer's Disease ...
(learn more by clicking here)
November 14, 2000
- Annual general meeting and first quarter results
Neurochem Inc. (TSX : NRM) held its first annual general meeting today in Montreal.
Dr. Louis R. Lamontagne, Neurochem's President and Chief Executive Officer, outlined the
Company's strategy ...
(learn more by clicking here)
November 8, 2000
- Neurochem files a request to begin phase II/III clinical trials in U.K. for
Fibrillex™
Neurochem Inc. (TSX : NRM) has submitted an application to the Clinical Trials Unit of
the Medicines Control Agency in the United Kingdom for initiation of a pivotal Phase II/III
clinical study ...
(learn more by clicking here)
October 31, 2000
- Neurochem files for Orphan Medicinal Product Designation in Europe for
Fibrillex™
Neurochem Inc. (TSX : NRM) has filed for "Orphan Medicinal Product" (OMP)
designation with the European Agency for the Evaluation of Medicinal Products (EMEA)
for Fibrillex™, a ...
(learn more by clicking here)
October 25, 2000
- Canaccord Capital Corporation initiates coverage of Neurochem
Neurochem Inc. (TSX : NRM) today announced that Canaccord Capital Corporation analyst, Mr.
Wayne Schnarr, has initiated coverage of the Company. "Canaccord is now the second
firm to ...
(learn more by clicking here)
October 11, 2000
- FDA grants Investigational New Drug (IND) status to Neurochem for
Fibrillex™
pivotal phase II/III on schedule.
Neurochem Inc. (TSX : NRM) announced today that it received Investigational New Drug (IND)
status for its lead drug candidate Fibrillex™
from the United States Food and Drug Administration ...
(learn more by clicking here)
October 6, 2000
- Dr. Louis R. Lamontagne, President and CEO of Neurochem Inc. interviewed by
Wall Street Reporter Magazine.
Neurochem Inc. (TSX : NRM) President and CEO, Dr. Louis R. Lamontagne was interviewed
on September 29, 2000, by John Foley, Senior Analyst at the Wall Street Reporter Magazine.
The interview ....
(learn more by clicking here)
October 5, 2000
- First International Conference On Hemmorrhagic Stroke Due To Cerebral Amyloid Angiopathy.
Neurochem Inc. (TSX : NRM) The First International Conference on Cerebral Amyloid
Angiopathy (CAA) is being hosted by the Massachusetts General Hospital in Boston.
Supported by Neurochem ...
(learn more by clicking here)
October 4, 2000
- Neurochem Inc. Announces Year-End Results.
Neurochem Inc. (TSX : NRM) today reported its year-end results for fiscal year 2000.
The Company reported a net loss of $ 5,581,000 or $ 0.44 per common share for the
year ended June 30, 2000 ....
(learn more by clicking here)
September 19, 2000
- Loewen, Ondaatje, McCutcheon Ltd. initiates coverage of Neurochem.
Neurochem Inc. (TSX : NRM) today announced that Loewen, Ondaatje, McCutcheon (LOM) has
initiated coverage of the Company. Copies of the report can be obtained by contacting
Neurochem. ....
(learn more by clicking here)
September 11, 2000
- Neurochem Files IND Submission to FDA for Lead Candidate in Treament of Secondary
Amyloidosis.
Neurochem Inc. (TSX : NRM) today announced that it has submitted an Investigational
New Drug (IND) application for its lead drug candidate Fibrillex
™ to the U.S. Food and Drug Administration ...
(learn more by clicking here)
August 24, 2000
- Underwriters of Neurochem Inc. Exercise Over-Allotment
Option for Gross Proceed of $36.8 Million.
Neurochem Inc. (TSX : NRM) A biopharmaceutical company focused on the development of
therapeutic treatments for a number of important diseases, including Alzheimer's disease,
announced today that ...
(learn more by clicking here)
June 22, 2000
- Neurochem Inc. Closes $32 Million Initial Public Offering.
Neurochem Inc. (TSX : NRM) announced today the closing of its initial public offering
consisting of a new issue of 3,878,787 Common Shares at a price of $8.25 per Share for
a total offering of $32,000,000...
(learn more by clicking here)
January 26, 2000
- Neurochem Inc. awarded $7.9 Million funding by Federal Technology Partnerships to
further development of its promising alzheimer treatement.
Neurochem Inc. (TSX : NRM) today announced that Technology Partnerships Canada (TPC) has
agreed to invest $7.9 million in the firm’s ground-breaking drug candidate for the
prevention and ...
(learn more by clicking here)
|
2008
Archives 1999
